All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the MDS Hub was delighted to speak to Lionel Ades, Saint-Louis Hospital, Paris, FR. We asked: what is the benefit of adding pevonedistat to azacitidine in patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)?

What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?

In this video, Lionel Ades describes the results of the phase II study that evaluated this combination in patients who had not previously received hypomethylating agents and were ineligible for stem cell transplant. He describes the event-free survival results of the 120 patients enrolled in the study as well as the overall survival and duration of response in the three patient populations: high-risk MDS, high-risk AML or low blast AML.

Share: